<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Oncology on FinanClub</title>
    <link>https://finan.club/tags/oncology/</link>
    <description>Recent content in Oncology on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Sat, 13 Apr 2024 09:02:18 +0000</lastBuildDate><atom:link href="https://finan.club/tags/oncology/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>GERN</title>
      <link>https://finan.club/us/gern/</link>
      <pubDate>Sat, 13 Apr 2024 09:02:18 +0000</pubDate>
      
      <guid>https://finan.club/us/gern/</guid>
      <description>score:78
Chances: Geron Corporation is developing a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies, which shows promising prospects in the field of oncology. The FDA&amp;rsquo;s potential expansion of the use of multiple myeloma cell therapies and other top-selling medicines indicates a favorable regulatory environment for Geron Corporation&amp;rsquo;s products.</description>
    </item>
    
  </channel>
</rss>
